TY  - GEN
AU  - Yee,Karen W L
AU  - Hagey,Anne
AU  - Verstovsek,Srdan
AU  - Cortes,Jorge
AU  - Garcia-Manero,Guillermo
AU  - O'Brien,Susan M
AU  - Faderl,Stefan
AU  - Thomas,Deborah
AU  - Wierda,William
AU  - Kornblau,Steven
AU  - Ferrajoli,Alessandra
AU  - Albitar,Maher
AU  - McKeegan,Evelyn
AU  - Grimm,David R
AU  - Mueller,Toby
AU  - Holley-Shanks,Rhonda R
AU  - Sahelijo,Leonardo
AU  - Gordon,Gary B
AU  - Kantarjian,Hagop M
AU  - Giles,Francis J
TI  - Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
SN  - 1078-0432
PY  - 2005///1108
KW  - AC133 Antigen
KW  - Acute Disease
KW  - Adult
KW  - Aged
KW  - Antigens, CD
KW  - analysis
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - CD146 Antigen
KW  - Constipation
KW  - chemically induced
KW  - Diarrhea
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - Endothelial Cells
KW  - chemistry
KW  - Female
KW  - Glycoproteins
KW  - Hematologic Neoplasms
KW  - blood
KW  - Humans
KW  - Leukemia
KW  - Leukocyte Common Antigens
KW  - Male
KW  - Microtubules
KW  - metabolism
KW  - Middle Aged
KW  - Mutation
KW  - Myelodysplastic Syndromes
KW  - Nausea
KW  - Neoplasm Recurrence, Local
KW  - Neoplastic Cells, Circulating
KW  - Neural Cell Adhesion Molecules
KW  - Peptides
KW  - Platelet Endothelial Cell Adhesion Molecule-1
KW  - Sulfonamides
KW  - Treatment Outcome
KW  - Tubulin
KW  - genetics
KW  - Vomiting
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-05-0650
ER  -